A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease
Journal of Virology · 22.10.2024 · 98 (10)
DOI: 10.1128/jvi.00638-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 22.10.2024. Verfasst von Victoria A Avanzato und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. Hauptthemen laut MEDLINE: Nipah Virus, Henipavirus Infections, Antibodies, Monoclonal, Viral Fusion Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, DOD | ARPA | Defense Sciences Office, DARPA (DSO), UKRI | Medical Research Council (MRC).
Abstract (Originalsprache)
Nipah virus (NiV) is a highly pathogenic paramyxovirus capable of causing severe respiratory and neurologic disease in humans. Currently, there are no licensed vaccines or therapeutics against NiV, underscoring the urgent need for the development of countermeasures. The NiV surface-displayed glycoproteins, NiV-G and NiV-F, mediate host cell attachment and fusion, respectively, and are heavily targeted by host antibodies. Here, we describe a vaccination-derived neutralizing monoclonal antibody, mAb92, that targets NiV-F. Structural characterization of the Fab region bound to NiV-F (NiV-F–Fab92) by cryo-electron microscopy analysis reveals an epitope in the DIII domain at the membrane distal apex of NiV-F, an established site of vulnerability on the NiV surface. Further, prophylactic treatment of hamsters with mAb92 offered complete protection from NiV disease, demonstrating beneficial activity of mAb92 in vivo . This work provides support for targeting NiV-F in the development of vaccines and therapeutics against NiV. IMPORTANCE Nipah virus (NiV) is a highly lethal henipavirus (HNV) that causes severe respiratory and neurologic disease in humans. Currently, there are no licensed vaccines or therapeutics against NiV, highlighting a need to develop countermeasures. The NiV surface displays the receptor binding protein (NiV-G, or RBP) and the fusion protein (NiV-F), which allow the virus to attach and enter cells. These proteins can be targeted by vaccines and antibodies to prevent disease. This work describes a neutralizing antibody (mAb92) that targets NiV-F. Structural characterization by cryo-electron microscopy analysis reveals where the antibody binds to NiV-F to neutralize the virus. This study also shows that prophylactic treatment of hamsters with mAb92 completely protected against developing NiV disease. This work shows how targeting NiV-F can be useful to preventing NiV disease, supporting future studies in the development of vaccines and therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
- Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
- Department of Infectious Diseases, King's College London, Guy's Hospital, London, United Kingdom.
ORCID-Profile: Victoria A Avanzato, Claude Kwe Yinda, Katie J Doores, Benhur Lee, Thomas A Bowden, Vincent J Munster
Förderung
- NIAID NIH HHS
- DOD | ARPA | Defense Sciences Office, DARPA (DSO)
- UKRI | Medical Research Council (MRC)
- Intramural NIH HHS
- NIGMS NIH HHS
- HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID)
- Wellcome Trust
- HHS | National Institutes of Health
Zitieren
APA
Avanzato, V. A., Bushmaker, T., Oguntuyo, K. Y., Yinda, C. K., Duyvesteyn, H. M. E., Stass, R., Meade-White, K., Rosenke, R., Thomas, T., van Doremalen, N., Saturday, G., Doores, K. J., Lee, B., Bowden, T. A., & Munster, V. J. (2024). A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease. Journal of Virology, 98(10). https://doi.org/10.1128/jvi.00638-24
Vancouver
Avanzato VA, Bushmaker T, Oguntuyo KY, Yinda CK, Duyvesteyn HME, Stass R, et al. A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease. Journal of Virology. 2024;98(10). doi:10.1128/jvi.00638-24
BibTeX
@article{Avanzato2024,
author = {Avanzato, Victoria A and Bushmaker, Trenton and Oguntuyo, Kasopefoluwa Y and Yinda, Claude Kwe and Duyvesteyn, Helen M E and Stass, Robert and Meade-White, Kimberly and Rosenke, Rebecca and Thomas, Tina and van Doremalen, Neeltje and Saturday, Greg and Doores, Katie J and Lee, Benhur and Bowden, Thomas A and Munster, Vincent J},
title = {A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease},
journal = {Journal of Virology},
year = {2024},
volume = {98},
number = {10},
doi = {10.1128/jvi.00638-24}
}
EUVIMED